New data analysis clarifies misleading benchmarks released by a competitor; separate SkylineDx analysis demonstrates Merlin CP-GEP Test provides stronger metastatic-risk stratification and superior ...
The MarketWatch News Department was not involved in the creation of this content. SkylineDx Publishes Landmark MERLIN_001 Trial in JAMA Surgery Validating the Predictive Power of the Merlin CP-GEP ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results